Otsuka opts out of Cimzia in Japan as UCB alliance reshaped
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical is to end its involvement in the Japanese development and commercialisation of UCB's pegylated antibody certolizumab pegol (Cimzia), although the firms will continue to work together on two other launched UCB products in the CNS field.